Chronic hepatitis B (CHB) infection is a serious and prevalent health concern worldwide, and the development of effective drugs and strategies to combat this disease is urgently needed. Currently, pegylated interferon-alpha (peg-IFNα) and nucleoside/nucleotide analogues (NA) are the most commonly prescribed treatments. However, sustained response rates in patients remain low, and the reasons are not well understood. Here, we observed that CHB patients preferentially harbored CD3 . In addition, regulatory T cells are increased and have an immunosuppressive effect on HBV-specific T helper cells in chronic hepatitis B (CHB) patients 5 . The findings described above provide valuable information for understanding HBV pathogenesis and immune-evasion mechanisms. However, immune indexes that reflect the therapeutic efficacy of HBV treatments have not been so reliable, and other ways to evaluate therapeutic efficacy are needed.
T cells in CHB patients may be useful as a new indicator associated with poor therapeutic responses to peg-IFNα treatment.
The hepatitis B virus (HBV) infects more than 350 million people worldwide and is a major cause of chronic liver disease 1 . Both the innate and adaptive immune responses in the host regulate HBV infection 2 . In the innate immune response, hepatic natural killer (NK) cells exert their antiviral function against HBV infection by killing infected cells and producing high cytokine levels, which both promote the pathogenesis of viral hepatitis 3 . In the adaptive immune response, HBV-specific CD8 + T cells lyse infected hepatocytes and control viral infection; indeed, impaired CD8 + T cell activity is associated with the establishment of chronic HBV infection 4 . In addition, regulatory T cells are increased and have an immunosuppressive effect on HBV-specific T helper cells in chronic hepatitis B (CHB) patients 5 . The findings described above provide valuable information for understanding HBV pathogenesis and immune-evasion mechanisms. However, immune indexes that reflect the therapeutic efficacy of HBV treatments have not been so reliable, and other ways to evaluate therapeutic efficacy are needed.
Thus far, only three major clinical regimens to treat HBV are available: peg-IFNα , nucleoside/nucleotide analogues (NA), and the combination of peg-IFNα plus NA therapy 6 . Unlike HCV treatment that has yielded encouraging results, the effect of various therapies on HBV has been rather poor regardless of the treatment strategy. For instance, loss of hepatitis B e antigen (HBeAg)-a readout of reduced viral infectivity after treatment-occurs in only 30% of HBeAg-positive CHB patients treated with peg-IFNα , while the remaining 70% do not respond to treatment 7 . However, the underlying reason for this treatment resistance in HBV patients remains unknown.
A subset of the human T cell population expresses CD56, an NK cell surface marker. Generally, CD56
+ T cells constitute approximately 10% of peripheral blood T cells and nearly 50% of liver T cells 8, 9 . Upon stimulation, CD56
+ T cells are activated, proliferate, and exhibit cytotoxicity in an MHC-unrestricted manner 10, 11 . Notably, CD56
+ T cells are a superior latent source of IFN-γ , which is considered to be a main mediator of antiviral responses 12 .
As an abundant T cell subset in the liver, CD56
+ T cells inhibit hepatic viral infection and replication, including HBV and HCV 13, 14 . Moreover, CD56 + T cells are competent to treat a number of various infectious diseases [15] [16] [17] [18] [19] . Despite this observed antiviral function, however, effector immune cells are always weaker in the context of HBV infection. We previously reported that TGFβ 1 enrichment in HBV-persistent patients reduced NKG2D/2B4 expression on NK cells, leading to NK cell suppression 20 . In CHB patients, high NKG2A expression on NK cells decreased NK cell cytotoxicity 21 . Additionally, CHB patients reportedly harbor CD56 + T cells that display significantly increased inhibitory T cell immunoglobulin mucin-3 (Tim-3) expression over those from healthy controls, and this expression is further upregulated in patients with acute-on-chronic liver failure 22 . Tim-3 expression on CD56 + T cells also closely correlated with elevated serum ALT levels (a readout of liver injury) in CHB patients. Taken together, we speculate that CD56 + T cells may be in diminished antiviral status in CHB patients. In order to understand the state of the immune system in CHB patients during HBV therapy, we evaluated new cases of untreated CHB patients who were systematically treated with peg-IFNα for 48 weeks. We identified that CHB patients could be classified into the following two different groups based on the intensity of CD3 expression on their CD56 + T cells: the CD3 bright CD56 + T cell-and CD3 dim CD56 + T cell-harboring CHB patient groups. Interestingly, a higher percentage of CHB patients (55/85, 64.7%) preferentially harbored the CD3 bright CD56 + T cells than healthy controls (10/33, 30.3%). We further found that CD56 + T cells played an important role in the host response to peg-IFNα therapy and that the presence of peripheral CD3 bright CD56 + T cells counted against host control of HBV and predicted poor therapeutic response. Indeed, CD3 bright CD56 + T cells appeared to be both phenotypically and functionally inhibited. CD3 bright CD56 + T cells rapidly upregulated Tim-3 expression during peg-IFNα treatment, which might explain the observed CD3 bright CD56 + T cell dysfunction. Taken together, we provide a possible immunological explanation as to why a majority of CHB patients have a poor therapeutic response to peg-IFNα and present a new clinical outcome indicator that may serve as an auxiliary measurement of the efficacy of peg-IFNα treatment.
Results

A majority of CHB patients preferentially harbor a CD3
bright CD56 + T cell population. Based on previous studies, CD56 + T cells may represent a unique cell population with a significant immunoregulatory role in CHB patients. To further characterize these CD56
+ T cells, we analyzed this cell population in live PBMC lymphocytes from 85 CHB patients and 33 healthy control individuals by flow cytometry ( Fig. 1 and Supplementary  Fig. S1A and S1B). We found that the mean fluorescence intensity (MFI) of CD3 expression was significantly higher on CD56 + T cells from CHB patients than from healthy controls, a difference not observed on conventional CD3 + CD56 − T cells ( Fig. 2A,B) . We then assessed the ratio of CD3 MFI between CD56 + T and conventional CD3
+ CD56 − T cell populations (relative CD3 MFI) and found that CHB patients displayed significantly higher relative CD3 MFI than healthy controls (Fig. 2C) , further demonstrating the higher CD3 MFI expression on CD56 + T cells in CHB patients. As illustrated by the vertical dashed line in the representative patient samples shown in Fig. 2A , CHB patients clearly exhibited a higher overall CD3 MFI on their CD56 + T cells (called "CD3 bright CD56 + T cells" here) than healthy controls, which harbored more of what we referred to as "CD3 dim CD56 + T cells". In order to distinguish them quantitatively, we analyzed the relative CD3 MFI from CHB patients based on that from healthy controls using the receiver operating characteristic (ROC) curve, and determined the cut-off ( Supplementary  Fig. S2 ). Using these designations, we classified each individual CHB patient and healthy control into one of two groups: one group that primarily harbored CD3 bright CD56 + T cells and another group that primarily harbored CD3 dim CD56 + T cells. Of the 85 total CHB patients enrolled in the study ( (Fig. 2D) , even though the frequency of CD56 + T cells in PBMCs remained similar between CHB patients and healthy controls (Fig. 2E) . We also confirmed that + (right) T cells in their respective CHB patient groups. Cumulative data for CD3 MFI were shown, respectively. Error bars, s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. N.S., not significant. this difference in CD3 MFI expression occurred only in CD56
+ , but not conventional T cells in CHB patients (Fig. 2F ). Taken together, these results suggest that CHB patients preferentially harbor CD3 bright CD56 + T cells.
CHB patients harboring CD3
bright CD56 + T cells exhibit a poor therapeutic response to peg-IFNα. We next determined whether there was a correlation between the presence of CD3 bright CD56
+ T cells in CHB patients and their response to therapy. Among the 69 from the total 85 CHB patients who had complete clinical data, we found that the clinical indexes of CHB patients harboring the CD3 bright CD56 + T cell population were significantly higher at different time points after treatment (Fig. 3A) . According to the EASL clinical practice guideline, response was defined as HBeAg loss with HBV DNA < 2000 IU/mL and ALT normalization at 24 weeks after treatment (72w), we compared the CD3 MFI on CD56
+ T cells between the responders and nonresponders and found that the CD3 MFI on CD56 + T cells was significantly higher in nonresponders compared to responders (Fig. 3B) ; assessment of the relative CD3 MFI on CD56
+ T cells between the responders and nonresponders revealed similar results (Fig. 3C) . Furthermore, the relative CD3 MFI was notably higher in nonresponders since peg-IFNα treatment (Fig. 3D) , and a larger proportion of CHB patients harboring CD3 bright CD56 + T cells (42/47, 89.4%) were nonresponsive to the treatment than the patients harboring CD3 dim CD56 + T cells (13/22, 59.1%) (Fig. 3E ). As previously reported 23 , CHB patients exhibiting HBsAg > 20000 IU/mL at 12 or 24 weeks on peg-IFNα therapy were advised to discontinue therapy due to the low probability of achieving a sustained response. Within our patient population, 12/85 exhibited HBsAg > 20000 IU/mL at 12 or 24 weeks; 10 of these harbored the CD3 bright CD56 + T cells ( Fig. 3F ) and maintained high HBsAg expression until the end of the therapy. Collectively, these results suggested that CHB patients harboring CD3 bright CD56 + T cells exhibited a relatively poor therapeutic response to peg-IFNα treatment.
CD3
bright CD56 + T cells express low CD8 levels. + T cells (Fig. 4A ,B); no differential CD4 expression was observed between the two groups ( Fig. 4A,C) . We also examined expression of the activation-related molecule CD69, maturation-related molecule CD57, and cytotoxicity-related molecule CD16, but did not observe any significant differences ( Supplementary  Fig. S3A-S3C) .
We next compared CD8 and CD3 expression on CD56 + T cells and found that CD8 expression in CD56 + T cells negatively correlated with the relative CD3 expression in all CHB patients (Fig. 4D) . Indeed, CD8 expression on CD56 + T cells in CHB patients harboring CD3 bright CD56 + T cells was significantly lower than on those in CHB patients harboring CD3 dim CD56 + T cells, even after peg-IFNα treatment (Fig. 4E) . Meanwhile, no significant differences were observed on CD69, CD57, and CD16 expression during therapy ( Supplementary Fig. S3D-S3F ). With respect to the treatment effect, nonresponsders had the lowest frequency of CD8 +
CD56
+ T cells, indicating that nonresponders might harbor more dysfunctional CD56 + T cells than responders (Fig. 4F) + T cells (Fig. 5A,B) ; similar results were observed for its heterodimer CD94 (Fig. 5A,C) . In contrast, no significant differences in expression of other inhibitory molecules, such as PD-1 and CTLA-4, were detected ( Supplementary Fig. S4A and S4B) . Furthermore, NKG2A expression on CD56
+ T cells exhibited a remarkable positive correlation with CD3 expression in all CHB patients (Fig. 5D) and S4D). With respect to the treatment effect, nonresponders had the highest frequency of NKG2A + CD56 + T cells compared to responders (Fig. 5F) Fig. 6B and Supplementary Fig. S6B ). During peg-IFNα therapy, IFNγ and CD107a expression in CD3 bright CD56 + T cells were consistently lower throughout the treatment period (Fig. 6C) . With respect to the treatment effect, nonresponders had the lower frequency of IFNγ + CD56 + and CD107a + CD56 + T cells compared to responders (Fig. 6D) compared to CD3 dim CD56 + T cells. (Fig. 6E) . Thus, our results suggested that CD3 bright CD56 + T cells had dysfunctional antiviral activity.
Tim-3 upregulation correlates with CD3
bright
CD56
+ T cell dysfunction during peg-IFNα treatment.
Tim-3 reportedly suppresses several effector cells in CHB patients 26, 27 . We therefore speculated that (Fig. 7A,B) . Moreover, Tim-3 expression on CD3 bright CD56 + T cells negatively correlated with IFNγ secretion, whereas Tim-3 and IFNγ expression exhibited a similar pattern on CD3 dim CD56
+ T cells (Fig. 7C) . Indeed, we confirmed the lower frequency of IFNγ on Tim3 + CD56 + T cells compared to that on Tim3 -CD56 + T cells (Fig. 7D) . Taken together, the negative correlation between Tim-3 upregulation and IFNγ secretion on CD56
+ T cells might provide a plausible explanation for the observed CD3 bright CD56 + T cell dysfunction during peg-IFNα treatment in CHB patients harboring this CD56
+ T cell population ( Supplementary Fig. S7 ).
Discussion
Previous reports found that CD56 + T cells played a key role in determining the outcome of acute HCV infection 28 . However, the sustained role of CD56 + T cells in regulating HBV infection during peg-IFNα treatment is largely unknown. Our results revealed that a majority of CHB patients preferentially harbor CD3 bright CD56
+ T cells compared to healthy controls and that the presence of this population could act as an auxiliary predictor of peg-IFNα efficacy during the treatment period. Based on the intensity of CD3 MFI on CD56
+ T cells, we are the first to reveal two phenotypically and functionally different CD56
+ T cell populations and that the CD3 bright CD56 + T cell population occurs more frequently in CHB patients than CD3 dim CD56
+ T cells. CD3 bright CD56 + T cells were phenotypically and functionally in an inhibited state, which included higher inhibitory NKG2A/CD94 expression as well as lower CD8 expression. Moreover, CD3 bright CD56 + T cells exhibited lower IFNγ secretion, considered to be the main driving force of the antiviral response against HBV. Peg-IFNα treatment did not improve the CD3 bright CD56 + T cell inhibitory state, as high NKG2A/CD94 and low CD8 expression was maintained during treatment. Consistent with the inhibitory phenotype and function of CD3 bright CD56 + T cells, CHB patients harboring these CD3 bright CD56 + T cells had relatively poor responses to peg-IFNα treatment. Finally, our data demonstrating that Tim-3 expression was rapidly upregulated on CD3 bright CD56
+ T cells during peg-IFNα treatment might provide a mechanistic understanding of the observed T cell dysfunction in CHB patients.
Previous clinical studies suggested the use of several viral outcome predictors to show an adjunctive measure of HBeAg seroconversion for evaluating peg-IFNα treatment efficacy in HBV patients 23, 29, 30 . However, these predictors were obtained several weeks after treatment began, whereas the ideal predictor would be assessed before treatment to identify patients that were not likely to respond to therapy. Here, our results suggest that the presence of the CD3 bright CD56 + T cell population in CHB patients can be used as a novel immunological predictor that can be easily detected before clinical peg-IFNα treatment, and it can also provide a new auxiliary indicator for evaluating the efficacy of peg-IFNα treatment of CHB patients during therapy.
A certain proportion of CHB patients in this study were assigned to receive peg-IFNα -2b in combination with adefovir dipivoxil (ADV). To investigate whether the treatment regimen affects the frequency of CD3 bright CD56
+ T cells, we compared the relative CD3 MFI of CD56 + T cells from patients treated with either PEG-IFNα or + (lower) T cells at a 1:10 ratio via transwell system. HBV DNA were determined. Error bars, s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. PEG-IFNα plus ADV at the indicated time points since peg-IFNα treatment. However, no significant differences were detected at any time point since peg-IFNα treatment (Supplementary Fig. S8 ). In addition, CD3 bright CD56
+ T cells expressed lower CD8 levels and higher NKG2A levels than CD3 dim CD56 + T cells regardless of treatment regimens ( Supplementary Fig. S9A and S9B) . Thus, treatment regimen does not affect the frequency of CD3 bright CD56
+ T cells. Tim-3 functions as a negative regulatory receptor for both innate and adaptive immune effector cells. It is already known to mediate NK cell suppression in HBV infection 31 . In terms of regulating T cells in HBV infection, Tim-3 upregulation in CHB patients contributes to T cell inhibition and deletion, and Tim-3 blockade enhances the antiviral function of HBV-specific T cells 32 . Our present results showed that Tim-3 expression rapidly increased on CD3 bright CD56 + T cells in CHB patients after peg-IFNα treatment and closely correlated with the decrease in antiviral IFNγ secretion. Thus, based on the evidence here and in previous studies, we speculate that the upregulation of Tim-3 on CD3 
Methods
Patients, healthy controls, and peg-IFNα treatment. Data presented in this study were obtained from 85 new cases of HBeAg-positive CHB patients (Table 1 ) and 33 healthy controls. All HBV samples were collected at the Department of Infectious Diseases from June 2012 to July 2014, and peripheral blood samples from healthy controls were collected at the Department of Clinical Laboratory (the First Affiliated Hospital of Anhui Medical University).
The peripheral blood samples of all HBV patients in the study had detectable baseline serum HBV DNA (> 2 × 10 4 IU/ml) and elevated serum ALT (> 2 × ULN and < 10 × ULN). Reasons for exclusion were as follows: presence of serum antibodies against HCV, HDV or HIV, liver cirrhosis, acquired or inherited liver disease, prior antiviral or immunomodulatory treatment.
CHB patients were randomly assigned to two different treatment groups: 1.5 μ g/kg PEG-IFNα -2b (PegIntron, Schering-Plough, Kenilworth, NJ, USA) weekly or peg-IFNα -2b weekly in combination with 10 mg adefovir dipivoxil (ADV, Hepsera, Gilead Sciences, Foster City, CA, USA) daily. Therapeutic regimens continued for 48 weeks and were followed by a 24-week post-treatment observation period. 
Reagents and antibodies.
The following antibodies were purchased from BD Pharmingen: APC-Cy7-anti-CD3, Alexa-647-anti-CD56, PE-Cy7-anti-CD8, PerCP-Cy5.5-anti-CD4, FITC-anti-CD94, FITVanti-IFN-γ , and PE-anti-CD107a. The following antibodies were purchased from R&D Systems: PE-anti-NKG2A and PE-anti-Tim-3. Isotype-matched negative control antibodies were all purchased from BD Pharmingen. Red blood cell (RBC) lysis buffer was purchased from BioLegend.
Immunostaining. After removing plasma from blood samples, the indicated fluorochrome-conjugated monoclonal antibodies were added to 100 μ L whole blood. The red blood cells were lysed with RBC lysis buffer using standard procedures. Stained cells were collected using an LSR II flow cytometer (BD Biosciences), and data were analyzed using FlowJo analysis software 7.6.1 (Tree Star, Inc. Intracellular IFN-γ and CD107a detection. PBMCs (5 × 10 6 /mL) from CHB patients were stimulated with PMA (30 ng/mL, Sigma) and ionomycin (1 μ g/mL, Calbiochem). Monensin (2.5 μ g/mL, Sigma) was added to prevent secretion of the induced cytokines into the supernatant, and cells were cultured at 37 °C and 5% CO 2 for 4 h. Cells were then harvested and labeled with Alexa-647-anti-CD56 and APC-Cy7-anti-CD3 for 30 min at 4 °C. After fixation and permeabilization, cells were stained with FITC-anti-IFN-γ or isotype negative control for 1 h at 4 °C. Degranulating cells were detected by culturing cells in the presence of PE-anti-CD107a for 4 h before surface staining. Cells were collected and analyzed after being washed with permeabilization buffer.
Primary CD56
+ T cell purification. CD56
+ T cells were enriched from peripheral blood mononuclear cells of CHB patients with CD3
+ CD56 + T Cell Isolation Kit (Miltenyi Biotec). The purity of CD56 + T cells measured by flow cytometry was greater than 95%. Purified CD56
+ T or CD56 -T cells were cultured in RPMI 1640 containing 10% fetal bovine serum (HyClone).
CD56
+ T cells stimulation in vitro. 1 × 10 6 fresh PBMCs from CHB patients were stimulated with or without recombinant human IL-12 (rhIL-12; 10 ng/mL, Peprotech) for 16 h, and IFNγ production by CD56 Virological assessment. Serum HBV DNA levels were quantified using Roche COBAS TaqMan HBV Test (F. Hoffmann-La Roche Ltd., Basel Switzerland), with the lower detection limit threshold set at 20 IU/ml. Serum HBsAg levels were quantified using Roche Elecsys HBsAg II quant assay (Roche Diagnostics, China; the lower detection limit threshold was 0.05 IU/mL). The quantification of serum HBeAg and anti-HBe levels were performed based on the cut-off index (COI) by Roche Elecsys 2010 immunoanalyzer (Roche Diagnostics, China). ALT was measured locally in accordance with standard procedures. HBV genotype was performed using genotype-specific primers 33 . Response to treatment was defined as a composite endpoint of HBeAg loss with HBV DNA level <2,000 IU/mL (~10,000 copies/mL) and ALT normalization at the end of 72 weeks (48 weeks of treatment and 24 weeks of follow-up) 30 .
Statistics.
A two-tailed Student's t-test was used to statistically compare differences between two groups. A two-way ANOVA test was used to statistically compare differences among multiple groups at different time points after treatment. Data are expressed as mean ± standard error of the mean (s.e.m.). Statistical analyses were performed with Prism 6 (GraphPad Software, Inc.) or SPSS Statistics version 22 (IBM). Differences achieving values of P < 0.05 were considered to be statistically significant.
